Wednesday, April 17, 2024
9:51 AM EST – Numinus Wellness Inc. : Announced that its research site, Cedar Clinical Research, has been chosen as one of multiple sites for Cybin’s Phase 3 pivotal, multinational clinical trial of CYB003 for the adjunctive treatment of Major Depressive Disorder. Numinus Wellness Inc. (T.NUMI) shares were unchanged at 0.07.
Stocks in Play: Numinus Wellness Inc., Wed, 17 Apr 2024 09:57:06 EST